Mutational analysis of genes coding for cell surface proteins in colorectal cancer cell lines reveal novel altered pathways, druggable mutations and mutated epitopes for targeted therapy

Donnard, E; Asprino, PF; Correa, BR; Bettoni, F; Koyama, FC; Navarro, FC; Perez, RO; Mariadason, J; Sieber, OM; Strausberg, RL; Simpson, AJ; Jardim, DL; Reis, LF; Parmigiani, RB; Galante, PA; Camargo, AA

Author(s): Donnard, E; Asprino, PF; Correa, BR; Bettoni, F; Koyama, FC; Navarro, FC; Perez, RO; Mariadason, J; Sieber, OM; Strausberg, RL; Simpson, AJ; Jardim, DL; Reis, LF; Parmigiani, RB; Galante, PA; Camargo, AA;
Details: Publication Year 2014-08-25,Volume 5,Issue #19,Page 9199-9213
Journal Title: Oncotarget
Publication Type: Journal Article
Abstract: We carried out a mutational analysis of 3,594 genes coding for cell surface proteins (Surfaceome) in 23 colorectal cancer cell lines, searching for new altered pathways, druggable mutations and mutated epitopes for targeted therapy in colorectal cancer. A total of 3,944 somatic non-synonymous substitutions and 595 InDels, occurring in 2,061 (57%) Surfaceome genes were catalogued. We identified 48 genes not previously described as mutated in colorectal tumors in the TCGA database, including genes that are mutated and expressed in >10% of the cell lines (SEMA4C, FGFRL1, PKD1, FAM38A, WDR81, TMEM136, SLC36A1, SLC26A6, IGFLR1). Analysis of these genes uncovered important roles for FGF and SEMA4 signaling in colorectal cancer with possible therapeutic implications. We also found that cell lines express on average 11 druggable mutations, including frequent mutations (>20%) in the receptor tyrosine kinases AXL and EPHA2, which have not been previously considered as potential targets for colorectal cancer. Finally, we identified 82 cell surface mutated epitopes, however expression of only 30% of these epitopes was detected in our cell lines. Notwithstanding, 92% of these epitopes were expressed in cell lines with the mutator phenotype, opening new venues for the use of "general" immune checkpoint drugs in this subset of patients.
Publisher: Impact Journals
Research Division(s): Systems Biology And Personalised Medicine
Open Access at Publisher's Site: http://www.impactjournals.com/oncotarget/index.php?journal=oncotarget&page=article&op=view&path[]=2374
Terms of Use/Rights Notice: Copyright @ 2008-2014 Impact Journals, LLC. All rights reserved.ll site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License. PII: 2374

Creation Date: 2014-09-12 02:01:40